Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

[Ki67: a surfactant of mitotic chromosomes].

Albagli O, Pelczar H.

Med Sci (Paris). 2019 Oct;35(10):732-735. doi: 10.1051/medsci/2019146. Epub 2019 Oct 18. French. No abstract available.

PMID:
31625891
2.

The supply chain of human pancreatic β cell lines.

Scharfmann R, Staels W, Albagli O.

J Clin Invest. 2019 Sep 3;129(9):3511-3520. doi: 10.1172/JCI129484. Review.

3.

New α- and SIN γ-retrovectors for safe transduction and specific transgene expression in pancreatic β cell lines.

Albagli O, Maugein A, Huijbregts L, Bredel D, Carlier G, Martin P, Scharfmann R.

BMC Biotechnol. 2019 Jun 17;19(1):35. doi: 10.1186/s12896-019-0531-9.

4.

Modeling human pancreatic beta cell dedifferentiation.

Diedisheim M, Oshima M, Albagli O, Huldt CW, Ahlstedt I, Clausen M, Menon S, Aivazidis A, Andreasson AC, Haynes WG, Marchetti P, Marselli L, Armanet M, Chimienti F, Scharfmann R.

Mol Metab. 2018 Apr;10:74-86. doi: 10.1016/j.molmet.2018.02.002. Epub 2018 Feb 8.

5.

[The role of BET proteins in γ-retrovirus integration].

Albagli O, Pelczar H.

Med Sci (Paris). 2016 Dec;32(12):1071-1075. doi: 10.1051/medsci/20163212009. Epub 2017 Jan 3. French. No abstract available.

6.

Mass production of functional human pancreatic β-cells: why and how?

Scharfmann R, Didiesheim M, Richards P, Chandra V, Oshima M, Albagli O.

Diabetes Obes Metab. 2016 Sep;18 Suppl 1:128-36. doi: 10.1111/dom.12728. Review. Erratum in: Diabetes Obes Metab. 2016 Dec;18(12 ):1288.

PMID:
27615142
7.

Xenotropic retrovirus Bxv1 in human pancreatic β cell lines.

Kirkegaard JS, Ravassard P, Ingvarsen S, Diedisheim M, Bricout-Neveu E, Grønborg M, Frogne T, Scharfmann R, Madsen OD, Rescan C, Albagli O.

J Clin Invest. 2016 Mar 1;126(3):1109-13. doi: 10.1172/JCI83573. Epub 2016 Feb 22.

8.

[Punish or cherish: p53, metabolism and tumor suppression].

Albagli O.

Med Sci (Paris). 2015 Oct;31(10):869-80. doi: 10.1051/medsci/20153110013. Epub 2015 Oct 19. Review. French.

9.

Human fucci pancreatic Beta cell lines: new tools to study Beta cell cycle and terminal differentiation.

Carlier G, Maugein A, Cordier C, Pechberty S, Garfa-Traoré M, Martin P, Scharfmann R, Albagli O.

PLoS One. 2014 Sep 26;9(9):e108202. doi: 10.1371/journal.pone.0108202. eCollection 2014.

10.

Distinct effects of the soluble versus membrane-bound forms of the notch ligand delta-4 on human CD34+CD38low cell expansion and differentiation.

Lahmar M, Catelain C, Poirault S, Dorsch M, Villeval JL, Vainchenker W, Albagli O, Lauret E.

Stem Cells. 2008 Mar;26(3):621-9. Epub 2007 Nov 29.

12.

lyl-1 and tal-1/scl, two genes encoding closely related bHLH transcription factors, display highly overlapping expression patterns during cardiovascular and hematopoietic ontogeny.

Giroux S, Kaushik AL, Capron C, Jalil A, Kelaidi C, Sablitzky F, Dumenil D, Albagli O, Godin I.

Gene Expr Patterns. 2007 Jan;7(3):215-26. Epub 2006 Oct 11.

PMID:
17112790
13.

[Myc and cell competition in Drosophila].

Albagli O, Pelczar H.

Med Sci (Paris). 2006 Jun-Jul;22(6-7):621-5. French. Erratum in: Med Sci (Paris). 2006 Aug-Sep;22(8-9):695.

14.

The SCL relative LYL-1 is required for fetal and adult hematopoietic stem cell function and B-cell differentiation.

Capron C, Lécluse Y, Kaushik AL, Foudi A, Lacout C, Sekkai D, Godin I, Albagli O, Poullion I, Svinartchouk F, Schanze E, Vainchenker W, Sablitzky F, Bennaceur-Griscelli A, Duménil D.

Blood. 2006 Jun 15;107(12):4678-86. Epub 2006 Mar 2.

PMID:
16514064
15.

Development of a new bicistronic retroviral vector with strong IRES activity.

Martin P, Albagli O, Poggi MC, Boulukos KE, Pognonec P.

BMC Biotechnol. 2006 Jan 12;6:4.

16.

Microarray analysis of LIF/Stat3 transcriptional targets in embryonic stem cells.

Sekkaï D, Gruel G, Herry M, Moucadel V, Constantinescu SN, Albagli O, Tronik-Le Roux D, Vainchenker W, Bennaceur-Griscelli A.

Stem Cells. 2005 Nov-Dec;23(10):1634-42. Epub 2005 Aug 11.

17.

[Fli1 haploinsufficiency underlies Paris-Trousseau thrombopenia].

Raslova H, Favier R, Albagli O, Vainchenker W.

Med Sci (Paris). 2004 Nov;20(11):962-4. French. No abstract available.

18.

FLI1 monoallelic expression combined with its hemizygous loss underlies Paris-Trousseau/Jacobsen thrombopenia.

Raslova H, Komura E, Le Couédic JP, Larbret F, Debili N, Feunteun J, Danos O, Albagli O, Vainchenker W, Favier R.

J Clin Invest. 2004 Jul;114(1):77-84.

19.

Point mutations in BCL6 DNA-binding domain reveal distinct roles for the six zinc fingers.

Mascle X, Albagli O, Lemercier C.

Biochem Biophys Res Commun. 2003 Jan 10;300(2):391-6.

20.

Class II histone deacetylases are directly recruited by BCL6 transcriptional repressor.

Lemercier C, Brocard MP, Puvion-Dutilleul F, Kao HY, Albagli O, Khochbin S.

J Biol Chem. 2002 Jun 14;277(24):22045-52. Epub 2002 Apr 19.

21.

Cell density-dependent induction of endogenous myogenin (myf4) gene expression by Myf5.

Lindon C, Albagli O, Pinset C, Montarras D.

Dev Biol. 2001 Dec 15;240(2):574-84.

22.

Colocalization and heteromerization between the two human oncogene POZ/zinc finger proteins, LAZ3 (BCL6) and PLZF.

Dhordain P, Albagli O, Honore N, Guidez F, Lantoine D, Schmid M, The HD, Zelent A, Koken MH.

Oncogene. 2000 Dec 14;19(54):6240-50.

24.

DNA replication progresses on the periphery of nuclear aggregates formed by the BCL6 transcription factor.

Albagli O, Lindon C, Lantoine D, Quief S, Puvion E, Pinset C, Puvion-Dutilleul F.

Mol Cell Biol. 2000 Nov;20(22):8560-70.

25.

Overexpressed BCL6 (LAZ3) oncoprotein triggers apoptosis, delays S phase progression and associates with replication foci.

Albagli O, Lantoine D, Quief S, Quignon F, Englert C, Kerckaert JP, Montarras D, Pinset C, Lindon C.

Oncogene. 1999 Sep 9;18(36):5063-75.

26.

The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression.

Dhordain P, Lin RJ, Quief S, Lantoine D, Kerckaert JP, Evans RM, Albagli O.

Nucleic Acids Res. 1998 Oct 15;26(20):4645-51.

27.

A conditional version of the Ets transcription factor Erm by fusion to the ligand binding domain of the oestrogen receptor.

Pelczar H, Albagli O, Chotteau-Lelievre A, Damour I, de Launoit Y.

Biochem Biophys Res Commun. 1997 Oct 9;239(1):252-6.

PMID:
9345304
28.

Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein.

Dhordain P, Albagli O, Lin RJ, Ansieau S, Quief S, Leutz A, Kerckaert JP, Evans RM, Leprince D.

Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10762-7.

29.

Expression of the PEA3 group of ETS-related transcription factors in human breast-cancer cells.

Baert JL, Monté D, Musgrove EA, Albagli O, Sutherland RL, de Launoit Y.

Int J Cancer. 1997 Mar 4;70(5):590-7.

30.

Function of ets genes is conserved between vertebrates and Drosophila.

Albagli O, Klaes A, Ferreira E, Leprince D, Klämbt C.

Mech Dev. 1996 Sep;59(1):29-40.

31.

Multiple domains participate in distance-independent LAZ3/BCL6-mediated transcriptional repression.

Albagli O, Dhordain P, Bernardin F, Quief S, Kerkaert JP, Leprince D.

Biochem Biophys Res Commun. 1996 Mar 27;220(3):911-5.

PMID:
8607866
32.

Two functionally distinct domains responsible for transactivation by the Ets family member ERM.

Laget MP, Defossez PA, Albagli O, Baert JL, Dewitte F, Stehelin D, de Launoit Y.

Oncogene. 1996 Mar 21;12(6):1325-36.

PMID:
8649835
33.

The BTB/POZ domain targets the LAZ3/BCL6 oncoprotein to nuclear dots and mediates homomerisation in vivo.

Dhordain P, Albagli O, Ansieau S, Koken MH, Deweindt C, Quief S, Lantoine D, Leutz A, Kerckaert JP, Leprince D.

Oncogene. 1995 Dec 21;11(12):2689-97.

PMID:
8545127
34.

The LAZ3/BCL6 oncogene encodes a sequence-specific transcriptional inhibitor: a novel function for the BTB/POZ domain as an autonomous repressing domain.

Deweindt C, Albagli O, Bernardin F, Dhordain P, Quief S, Lantoine D, Kerckaert JP, Leprince D.

Cell Growth Differ. 1995 Dec;6(12):1495-503.

35.

The BTB/POZ domain: a new protein-protein interaction motif common to DNA- and actin-binding proteins.

Albagli O, Dhordain P, Deweindt C, Lecocq G, Leprince D.

Cell Growth Differ. 1995 Sep;6(9):1193-8.

36.

A model for gene evolution of the ets-1/ets-2 transcription factors based on structural and functional homologies.

Albagli O, Soudant N, Ferreira E, Dhordain P, Dewitte F, Begue A, Flourens A, Stehelin D, Leprince D.

Oncogene. 1994 Nov;9(11):3259-71.

PMID:
7936650
37.

A residue of the ETS domain mutated in the v-ets oncogene is essential for the DNA-binding and transactivating properties of the ETS-1 and ETS-2 proteins.

Soudant N, Albagli O, Dhordain P, Flourens A, Stéhelin D, Leprince D.

Nucleic Acids Res. 1994 Sep 25;22(19):3871-9.

38.

The two functionally distinct amino termini of chicken c-ets-1 products arise from alternative promoter usage.

Crepieux P, Leprince D, Flourens A, Albagli O, Ferreira E, Stéhelin D.

Gene Expr. 1993;3(2):215-25.

39.

Phylogeny of the p68c-ets-1 amino-terminal transactivating domain reveals some highly conserved structural features.

Albagli O, Flourens A, Crepieux P, Begue A, Stehelin D, Leprince D.

Oncogene. 1992 Jul;7(7):1435-9.

PMID:
1620554

Supplemental Content

Loading ...
Support Center